KKR to invest in Precipart Group Ltd.

Kohlberg Kravis Roberts (KKR) has agreed to make a significant strategic investment in Precipart Group Ltd., a leading contract manufacturer of precision components for the medical device and aerospace industries. KKR plans to support the company in its continued growth organically and through M&A.

Precipart, founded in 1950 by the Laubscher family with roots in Swiss engineering and manufacturing, is a leading contract development and manufacturing organization of highly engineered precision components and assemblies, primarily for the medical device industry as well as the aerospace and industrial markets. Precipart, through its mission to Engineer Possible, is a comprehensive solution provider supporting its customers from the concept phase to serial production and in managing their growing supply chain complexity. Major product offerings include precision machining, micro mechanical components, assemblies, gear systems, motion solutions, technical ceramics and advanced 3D printing.

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people and supporting growth in its portfolio companies and communities. KKR is investing in Precipart through its Health Care Strategic Growth Fund, a fund dedicated to investing in high-growth healthcare-related companies to which KKR can be a unique strategic partner in helping reach scale.

The Laubscher family remains highly committed to Precipart and is retaining a significant minority ownership stake in the company.

Oaklins’ team in Switzerland acted as the exclusive sell-side advisor to the shareholders of Precipart in the transaction. Oaklins TM Capital approached potential investors in the US market and supported the transaction at its early stages.